Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Hepcidin Stories

2013-12-18 13:33:05

A UCLA research team has found no evidence of an association between iron levels in the body and the risk of atherosclerosis, the hardening and narrowing of the arteries that leads to cardiovascular disease, the No. 1 killer in the U.S. The discovery, based on a comprehensive study in a mouse model of atherosclerosis, contradicts a long-held hypothesis about the role of iron in the disease and carries important implications for patients with chronic kidney disease or anemia related to...

2013-06-10 08:29:22

CARLSBAD, Calif. and VANCOUVER, British Columbia, June 10, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Xenon Pharmaceuticals Inc. announced today that Xenon has exercised its option to an exclusive worldwide license to XEN701, an antisense drug discovered in a collaboration between Isis and Xenon. For the license of XEN701, Isis earns a $2 million payment from Xenon. XEN701 is a drug candidate designed to inhibit the production of hepcidin, a target Xenon identified...

2013-05-17 12:23:11

BOSTON, May 17, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest update for their competitive landscape map for the Chronic Kidney Disease (CKD) market. This particular landscape highlights over 90 international companies with drugs and devices currently on the market and in development addressing CKD and its sequelae. (Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) Topics include: hypertension - renal denervation diabetic nephropathy -...

2011-11-16 09:37:40

Researchers at Emory University School of Medicine have identified hepcidin, a hormone that regulates iron levels in the body, as a potential target for treating atherosclerosis. Suppressing hepcidin is a way to reduce the iron levels inside the white blood cells found in arterial plaques. Reducing iron levels pushes those cells to clean up harmful cholesterol in a process called "reverse cholesterol transport," interfering with atherosclerosis, researchers have found. The data is being...

2011-11-01 21:11:53

Multiple organs, including the liver and the heart, become damaged if an individual has an excessive amount of iron in their body. Treatments for iron overload are arduous and/or have severe side effects. A team of researchers led by Elizabeta Nemeth, at the University of California, Los Angeles, has now generated data in mice that suggest that they have designed a promising new approach to reducing iron overload. Iron overload is a hallmark of the genetic disease hereditary...

2011-11-01 21:09:49

Iron overload is a common condition affecting millions of people worldwide. Excess iron in the body is toxic, and deposits can cause damage to the liver, heart and other organs. Current treatments, researchers say, are not ideal and have significant side effects. Iron in the body is regulated by a hormone called hepcidin, and a deficiency in this hormone can cause the iron overload seen in genetic disorders like hereditary hemochromatosis and Cooley's anemia. In the hopes of finding a...

2011-10-19 04:50:00

FREISING, Germany, October 19, 2011 /PRNewswire/ -- The EUROCALIN Consortium, comprising 10 companies and universities from across Europe, has initiated a collaboration focused on attaining and completing initial clinical development of a novel Anticalin(R) therapeutic. The project will be funded in large part by the European Commission Seventh Framework Programme (FP7-Health.2011.1.4.3; grant agreement number 278408). Anticalins are novel, next generation therapeutic proteins...

2011-09-26 15:19:13

Researchers at Wake Forest Baptist Medical Center have made a discovery that brings them one step closer to being able to better predict which patients have the best chance of surviving breast cancer. The group has identified 16 genes, or proteins, all involved in iron metabolism, that provide better prognostic information than conventional, standard markers of prognosis. Last summer, some of the same investigators published a study showing that women who had high levels of a protein...

2011-05-23 04:00:00

FREISING, Germany, May 23, 2011 /PRNewswire/ -- Pieris AG announced today preclinical in vitro and in vivo data for its PRS-080 Anticalin antagonist program targeting hepcidin, a small peptide which plays a pivotal role in the regulation of iron levels in the blood. PRS-080 showcases Anticalins' ability to encapsulate small targets like hepcidin with high specificity and potency. The results of Pieris' PRS-080 studies are being presented at the International BioIron Society Meeting being...

2010-11-23 13:37:58

2 new studies illustrate how hepcidin affects beta-thalassemia and hemochromatosis diseases A hormone made by the body may be a potential therapeutic tool for the treatment of two anemic blood disorders -- beta-thalassemia and hemochromatosis. The new research was led by scientists at Weill Cornell Medical College and published in the Journal of Clinical Investigation and the journal Blood. Commonly known as Cooley's anemia, beta-thalassemia affects nearly 1,000 individuals in the United...